| 15.145 0.015 (0.1%) | 05-17 15:59 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 17.71 | 1-year : | 20.68 |
| Resists | First : | 15.16 | Second : | 17.71 |
| Pivot price | 15.09  |
|||
| Supports | First : | 14.86 |
Second : | 14.68 |
| MAs | MA(5) : | 15.13 | MA(20) : | 15.03 |
| MA(100) : | 14.37 |
MA(250) : | 13.17 |
|
| MACD | MACD : | 0.1  |
Signal : | 0.1 |
| %K %D | K(14,3) : | 82.2 |
D(3) : | 86.4 |
| RSI | RSI(14): 76.5 | |||
| 52-week | High : | 15.89 | Low : | 11.52 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ MACK ] has closed below upper band by 31.7%. Bollinger Bands are 63.8% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 2 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 15.14 - 15.22 | 15.22 - 15.28 |
| Low: | 14.95 - 15.04 | 15.04 - 15.11 |
| Close: | 15 - 15.13 | 15.13 - 15.25 |
Merrimack Pharmaceuticals, Inc. operates as a biopharmaceutical company. The company was incorporated in 1993 and is headquartered in Cambridge, Massachusetts.
Tue, 30 Apr 2024
Merrimack Pharmaceuticals plans NASDAQ delisting and liquidation - Investing.com
Wed, 04 Jan 2023
Merrimack Still Has Significant Arbitrage Potential (NASDAQ:MACK) - Seeking Alpha
Thu, 19 Sep 2019
Merrimack Pharmaceuticals Announces Changes to Board of Directors - Business Wire
Fri, 13 Oct 2017
Merrimack Announces Date of One-for-Ten Reverse Stock Split - PR Newswire
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 15 (M) |
| Shares Float | 10 (M) |
| Held by Insiders | 1.1 (%) |
| Held by Institutions | 62.9 (%) |
| Shares Short | 842 (K) |
| Shares Short P.Month | 723 (K) |
| EPS | -0.1 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 15.25 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -1.1 % |
| Return on Equity (ttm) | -1.2 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -2 (M) |
| Levered Free Cash Flow | 21 (M) |
| PE Ratio | -168.12 |
| PEG Ratio | 0 |
| Price to Book value | 0.99 |
| Price to Sales | 0 |
| Price to Cash Flow | -90.24 |
| Dividend | 15.1 |
| Forward Dividend | 0 |
| Dividend Yield | 99.8% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|